{"schema_version":"secwatch.filing_event.v1","accession":"0001555280-24-000141","form_type":"8-K","ticker":"ZTS","cik":"0001555280","company_name":"Zoetis Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.594500+00:00","generated_at":"2026-06-06T03:22:48.586241+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zoetis Q4 2023 revenue $2.2B (+8%), adj. EPS $1.24; FY2024 guidance $9.075-9.225B","bullets":["Q4 revenue $2.2B (+8% reported & operational); net income $525M ($1.14 diluted EPS), up 14% and 15% respectively.","Adjusted net income Q4 $569M ($1.24 diluted EPS), up 6% operational.","FY 2023 revenue $8.5B (+6% reported, +7% operational); net income $2.3B ($5.07 diluted EPS).","FY 2024 guidance: revenue $9.075-9.225B (operational growth 7-9%); adjusted diluted EPS $5.74-5.84.","Key growth drivers: Librela, Simparica Trio, dermatology; new approvals for Solensia in Brazil and Simparica Trio in China."],"urls":{"canonical":"https://secwatch.observer/filing/0001555280-24-000141","json":"https://secwatch.observer/filing/0001555280-24-000141.json","markdown":"https://secwatch.observer/filing/0001555280-24-000141.md","text":"https://secwatch.observer/filing/0001555280-24-000141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000141/0001555280-24-000141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000141/zts-20240213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:22:48.586241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b5d325dc776b47e66af1cd894eb6a2d6e373b65","claim":"Zoetis Inc. reported full year 2023 results: revenue $8.5 Billion, net income $2.3 Billion, EPS $5.07 per Diluted Share. Guidance initiated.","evidence_excerpt":"For Full Year 2023, Zoetis Reports Revenue of $8.5 Billion, Growing 6%, and Net Income of $2.3 Billion, or $5.07 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000141/0001555280-24-000141-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$8.5 Billion"},{"label":"Net income","value":"$2.3 Billion"},{"label":"EPS","value":"$5.07 per Diluted Share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8c9025dd465f77c06634cd303b576ed81c2d8b9c","claim":"Zoetis Inc. reported full year 2024 results: revenue $9.075 - $9.225 Billion, EPS $5.34 to $5.44 on a Reported Basis, or $5.74 to $5.84 on an Adjusted Basis. Guidance initiated.","evidence_excerpt":"Provides Full Year 2024 Revenue Guidance of $9.075 - $9.225 Billion, with Diluted EPS of $5.34 to $5.44 on a Reported Basis, or $5.74 to $5.84 on an Adjusted Basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000141/0001555280-24-000141-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"$9.075 - $9.225 Billion"},{"label":"EPS","value":"$5.34 to $5.44 on a Reported Basis, or $5.74 to $5.84 on an Adjusted Basis"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e77ac5f4e8512772ce2e7ea9e50c05451b951a81","claim":"Zoetis Inc. reported the fourth quarter and full year 2023 results: revenue $2.2 billion, net income $525 million, EPS $1.14 per diluted share. Guidance initiated.","evidence_excerpt":"Zoetis Reports Fourth Quarter and Full Year 2023 Results • For Fourth Quarter 2023, Zoetis Reports Revenue of $2.2 Billion, Growing 8%, and Net Income of $525 Million, or $1.14 per Diluted Share, Increasing 14% and 15%, Respectively, on a Reported Basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000141/0001555280-24-000141-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2023"},{"label":"Revenue","value":"$2.2 billion"},{"label":"Net income","value":"$525 million"},{"label":"EPS","value":"$1.14 per diluted share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}